# US 2012/0253035 A1 · 1,4-oxazepines as bace1 and/or bace2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253035 A1
- Document ID: US20120253035A1
- Status: Published application
- Kind: A1
- Application number: 13/432,003
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-04-04
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Robert Narquizian; Thomas Woltering; Wolfgang Wostl
- Web page: https://patentgrep.com/patent/US20120253035A1

## CPC

- C07D 413/10: linked by a carbon chain containing aromatic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 267/10: not condensed with other rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to 1,4 Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

## Claims

### Claim 1

A compound of formula I,
wherein
R1 is selected from the groups consisting of
hydrogen and
halogen;
R2 is selected from the groups consisting of
C1-6-alkyl and
halogen-C1-3-alkyl;
R3 is selected from the groups consisting of
hydrogen,
halogen, and
C1-6-alkyl;
R4 is selected from the groups consisting of
hydrogen,
halogen, and
C1-6-alkyl;
R5 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R6 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R7 and R8 together with the C atom to which they are attached form a group selected from the group consisting of
aryl,
aryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2—, C1-6-alkyl-SO2—, C1-6-alkoxy-SO2— and C1-6-alkyl,
heteroaryl,
heteroaryl substituted by 1-4 substituents individually selected from aryl, cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, halogen-C1-6-alkyl-heteroaryl, halogen-aryl, heteroaryl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2— and C1-6-alkyl,
C2-6-alkynyl,
C2-6-alkynyl substituted by 1-5 substituents individually selected from aryl, cyano, halogen-aryl, halogen, C1-6-alkyl, C1-6-alkyl-aryl, cyano-heteroaryl, halogen-heteroaryl, C1-6-alkyl-heteroaryl, heteroaryl, C1-6-alkoxy-heteroaryl and C1-6-alkoxy;
heterocyclyl, and
heterocyclyl substituted by 1-4 substituents individually selected from halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl;
R9 is selected from the group consisting of
halogen and
C1-6-alkyl; and
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
R1 is selected from the groups consisting of
hydrogen and
halogen;
R2 is selected from the groups consisting of
C1-6-alkyl and
halogen-C1-3-alkyl;
R3 is selected from the groups consisting of
hydrogen,
halogen, and
C1-6-alkyl;
R4 is selected from the groups consisting of hydrogen,
halogen, and
C1-6-alkyl;
R5 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R6 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R7 and R8 together with the C atom to which they are attached form a group selected from the group consisting of
aryl,
aryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2—, C1-6-alkyl-SO2—, C1-6-alkoxy-SO2— and C1-6-alkyl,
heteroaryl,
heteroaryl substituted by 1-4 substituents individually selected from aryl, cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, halogen-C1-6-alkyl-heteroaryl, halogen-aryl, heteroaryl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2— and C1-6-alkyl,
C2-6-alkynyl,
C2-6-alkynyl substituted by 1-5 substituents individually selected from aryl, cyano, halogen-aryl, halogen, C1-6-alkyl, C1-6-alkyl-aryl, C1-6-alkyl-heteroaryl and C1-6-alkoxy;
heterocyclyl, and
heterocyclyl substituted by 1-4 substituents individually selected from halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl;
R9 is selected from the group consisting of
halogen and
C1-6-alkyl; and
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein
R1 is halogen;
R2 is C1-6-alkyl;
R3 is halogen;
R4 is halogen;
R5 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R6 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R7 and R8 together with the C atom to which they are attached form a group selected from the group consisting of
aryl substituted by 1-2 substituents individually selected from cyano, halogen, C1-6-alkyl-NH—SO2—, and C1-6-alkoxy-SO2,
heteroaryl,
heteroaryl substituted by 1-2 substituents individually selected from halogen, halogen-C1-6-alkyl-heteroaryl, halogen-aryl, heteroaryl, C1-6-alkoxy and C1-6-alkyl,
C2-6-alkynyl substituted by 1-2 substituents individually selected from halogen-aryl and C1-6-alkyl-heteroaryl, and
heterocyclyl;
R9 is halogen; and
n is 0 or 1.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R1 is halogen.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein R1 is F.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R2 is C1-6-alkyl.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein R2 is methyl.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R3 is halogen.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein R3 is F.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein R4 is halogen.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein R4 is F.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein R5 is C1-6-alkyl.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein R5 is methyl.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein R5 is hydrogen.

### Claim 15 (depends on 1)

The compound according to claim 1, wherein R6 is C1-6-alkyl.

### Claim 16 (depends on 15)

The compound according to claim 15, wherein R6 is methyl.

### Claim 17 (depends on 1)

The compound according to claim 1, wherein R6 is hydrogen.

### Claim 18 (depends on 1)

The compound according to claim 1, wherein R9 is halogen and n is 1.

### Claim 19 (depends on 18)

The compound according to claim 18, wherein R9 is F and n is 1.

### Claim 20 (depends on 1)

The compound according to claim 1, wherein n is 0.

### Claim 21 (depends on 1)

The compound according to claim 1, wherein R7 and R8 together with the C atom to which they are attached form a group selected from the group consisting of
aryl substituted by 1-2 substituents individually selected from cyano and halogen,
heteroaryl, and
heteroaryl substituted by 1-2 substituents individually selected from halogen.

### Claim 22 (depends on 1)

The compound according to claim 1, wherein R7 and R8 together with the C atom to which they are attached form a group selected from the groups consisting of phenyl substituted by halogen or cyano, pyrimidyl, and pyridinyl substituted by halogen.

### Claim 23 (depends on 1)

The compound according to claim 1, selected from the group consisting of
(R)-6,6-Difluoro-5-(2-fluoro-5-pyrimidin-5-yl-phenyl)-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-{5-[1-(3-Chloro-phenyl)-1H-pyrazol-4-yl]-2-fluoro-phenyl}-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-3-sulfonic acid 2,2-dimethyl-propyl ester,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-6,4′-difluoro-biphenyl-3-carbonitrile,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-3-caronitrile,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-3-sulfonic acid tert-butylamide,
5-[3-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-pyridine-3-sulfonic acid tert-butylamide,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-4-carbonitrile,
5′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-2′,4′-difluoro-biphenyl-4-carbonitrile and,
5′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-2′,4′-difluoro-biphenyl-3-carbonitrile
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1)

The compound according to claim 1, selected from the group consisting of
6-[3-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenylethynyl]-nicotinonitrile,
2-[3-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenylethynyl]-isonicotinonitrile,
(R)-6,6-Difluoro-5-(2-fluoro-5-pyrimidin-5-yl-phenyl)-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-(3′,5′-Dichloro-4-fluoro-biphenyl-3-yl)-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-(5′-Chloro-4,3′-difluoro-biphenyl-3-yl)-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-(2,4-Difluoro-5-pyrimidin-5-yl-phenyl)-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-(2-fluoro-5-pyridin-2-ylethynyl-phenyl)-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5,7,7-trimethyl-5-(4,3′,5′-trifluoro-biphenyl-3-yl)-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-{2,4-Difluoro-5-[1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-phenyl}-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[2,4-Difluoro-5-(6-trifluoromethyl-benzooxazol-2-yl)-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine, and
(R)-5-[5-(5-Chloro-pyridin-3-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine;
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

The compound according to claim 1, selected from the group consisting of
(R)-6,6-Difluoro-5-{2-fluoro-5-[1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-phenyl}-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-[2-fluoro-5-(2-methyl-2H-pyrazol-3-yl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-[2-fluoro-5-(tetrahydro-pyran-4-yl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(3-Chloro-phenylethynyl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-[2-fluoro-5-(2-methyl-thiazol-4-ylethynyl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(6-Chloro-benzooxazol-2-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(6-Chloro-benzothiazol-2-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-[2-fluoro-5-(1-pyridin-2-yl-1H-imidazol-4-yl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-{2-fluoro-5-[1-(5-trifluoromethyl-pyridin-2-yl)-1H-imidazol-4-yl]-phenyl}-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(3-Chloro-phenylethynyl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine, and
(R)-5-[5-(5-Chloro-pyridin-3-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

The compound according to claim 1, selected from the group consisting of
(R)-5-[5-(6-Chloro-benzooxazol-2-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(5-Chloro-pyrimidin-2-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(5-Chloro-pyrimidin-2-ylethynyl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(2-Chloro-pyridin-4-ylethynyl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(6-Chloro-pyridazin-3-ylethynyl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(5-Chloro-pyridin-3-ylethynyl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-[2-fluoro-5-(5-methoxy-pyrazin-2-ylethynyl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(5-Chloro-benzooxazol-2-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[2,4-Difluoro-5-(2-methoxy-pyrimidin-5-yl)-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(3,6-Dihydro-2H-pyran-4-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine, and
(R)-5-[5-(5,6-Difluoro-benzooxazol-2-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

The compound according to claim 1, selected from the group consisting of
(R)-6,6-Difluoro-5-(2-fluoro-5-pyrimidin-5-yl-phenyl)-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-(2,4-Difluoro-5-pyrimidin-5-yl-phenyl)-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-(3′,5′-Dichloro-4-fluoro-biphenyl-3-yl)-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-(5′-Chloro-4,3′-difluoro-biphenyl-3-yl)-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[2,4-Difluoro-5-(2-methoxy-pyrimidin-5-yl)-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(3,6-Dihydro-2H-pyran-4-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(3-Chloro-phenylethynyl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(3-Chloro-phenylethynyl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(5-Chloro-pyridin-3-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine, and
(R)-5-[5-(5-Chloro-pyridin-3-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine.
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1)

The compound according to claim 1, selected from the group consisting of
(R)-5-[5-(5-Chloro-pyrimidin-2-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(6-Chloro-benzooxazol-2-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(6-Chloro-benzooxazol-2-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(6-Chloro-benzothiazol-2-yl)-2-fluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-{2,4-Difluoro-5-[1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-phenyl}-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-{5-[1-(3-Chloro-phenyl)-1H-pyrazol-4-yl]-2-fluoro-phenyl}-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-(2-fluoro-5-pyrimidin-5-yl-phenyl)-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5,7,7-trimethyl-5-(4,3′,5′-trifluoro-biphenyl-3-yl)-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-[2-fluoro-5-(1-pyridin-2-yl-1H-imidazol-4-yl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine, and
(R)-6,6-Difluoro-5-[2-fluoro-5-(2-methyl-2H-pyrazol-3-yl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine.
(R)-6,6-Difluoro-5-[2-fluoro-5-(2-methyl-thiazol-4-ylethynyl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 1)

The compound according to claim 1, selected from the group consisting of
(R)-6,6-Difluoro-5-[2-fluoro-5-(tetrahydro-pyran-4-yl)-phenyl]-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-{2-fluoro-5-[1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-phenyl}-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-{2-fluoro-5-[1-(5-trifluoromethyl-pyridin-2-yl)-1H-imidazol-4-yl]-phenyl}-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-3-sulfonic acid tert-butylamide,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-3-sulfonic acid 2,2-dimethyl-propyl ester,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-6,4′-difluoro-biphenyl-3-carbonitrile,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-3-carbonitrile,
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4′-fluoro-biphenyl-4-carbonitrile,
5′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-2′,4′-difluoro-biphenyl-4-carbonitrile,
5′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-2′,4′-difluoro-biphenyl-3-carbonitrile, and
5-[3-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-pyridine-3-sulfonic acid tert-butylamide,
or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 1)

The compound according to claim 1, selected from the group consisting of
(R)-6,6-Difluoro-5-(2-fluoro-5-pyrimidin-5-yl-phenyl)-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine formate,
(R)-5-(2,4-Difluoro-5-pyrimidin-5-yl-phenyl)-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-5-[5-(5-Chloro-pyridin-3-yl)-2,4-difluoro-phenyl]-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine,
(R)-6,6-Difluoro-5-(2-fluoro-5-pyrimidin-5-yl-phenyl)-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine, and
3′-((R)-3-Amino-6,6-difluoro-5,7,7-trimethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-6,4′-difluoro-biphenyl-3-carbonitrile.

### Claim 31

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
wherein
R1 is selected from the groups consisting of
hydrogen and
halogen;
R2 is selected from the groups consisting of
C1-6-alkyl and
halogen-C1-3-alkyl;
R3 is selected from the groups consisting of
hydrogen,
halogen, and
C1-6-alkyl;
R4 is selected from the groups consisting of
hydrogen,
halogen, and
C1-6-alkyl;
R5 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R6 is selected from the groups consisting of
hydrogen and
C1-6-alkyl;
R7 and R8 together with the C atom to which they are attached form a group selected from the group consisting of
aryl,
aryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2—, C1-6-alkyl-SO2—, C1-6-alkoxy-SO2— and C1-6-alkyl,
heteroaryl,
heteroaryl substituted by 1-4 substituents individually selected from aryl, cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, halogen-C1-6-alkyl-heteroaryl, halogen-aryl, heteroaryl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C1-6-alkyl-NH—SO2— and C1-6-alkyl,
C2-6-alkynyl,
C2-6-alkynyl substituted by 1-5 substituents individually selected from aryl, cyano, halogen-aryl, halogen, C1-6-alkyl, C1-6-alkyl-aryl, cyano-heteroaryl, halogen-heteroaryl, C1-6-alkyl-heteroaryl, heteroaryl, C1-6-alkoxy-heteroaryl and C1-6-alkoxy;
heterocyclyl, and
heterocyclyl substituted by 1-4 substituents individually selected from halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl;
R9 is selected from the group consisting of
halogen and
C1-6-alkyl; and
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.
